

## PainChek partners with Eldermark to expand US market reach

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to announce a reseller and integration agreement with Eldermark Software LLC (“Eldermark”), a major provider of care management systems (CMS) in the United States.

This agreement, effective immediately and renewing automatically each year unless terminated prior to the renewal date, will enable Eldermark to offer PainChek’s digital pain assessment solution to its extensive network of long-term care clients across the US. Eldermark has been providing dedicated senior living solutions in the US and Canada for 30 years, with more than 116,000 client users.

Through this collaboration, PainChek aims to drive adoption of its innovative technology within a market increasingly focused on enhancing resident care and outcomes.

The partnership will include seamless integration of PainChek’s technology within Eldermark’s CMS platform, providing users with real-time access to advanced pain assessment tools powered by AI and facial recognition technology. By combining PainChek’s capabilities with Eldermark’s robust CMS infrastructure, the partnership seeks to improve the accuracy of pain management, reduce caregiver burden, and enhance quality of life for residents.

Eldermark CEO Jaime Ojeda stated:

*"We are thrilled to partner with PainChek to bring its state-of-the-art pain assessment solution to the US long-term care sector. As a leading provider of care management systems, this partnership aligns with our mission to empower caregivers with the tools they need to deliver exceptional care."*

PainChek CEO Philip Daffas commented:

*"This agreement with Eldermark is a key milestone as we expand our presence in the US market in anticipation of FDA clearance. We are excited to work alongside such a reputable partner to bring our technology to a broader audience and further support best-practice pain management."*

### Agreement Details

Under the terms of the reseller agreement:

- Scope: Eldermark will act as a non-exclusive reseller of PainChek’s Adult solution, targeting the US long-term care market. Actual sales into the USA will commence once PainChek receives FDA De Novo clearance for the PainChek Adult App.

For personal use only

- Integration: PainChek’s platform will be integrated into Eldermark’s CMS, ensuring ease of access for clients and supporting the PainChek sales process.

The financial impact cannot be quantified at the time of entry into the agreement, as it is a reseller agreement based on Eldermark’s best efforts to promote PainChek’s technology within its existing client base.

This release has been authorized for release by PainChek CEO Philip Daffas.

**For more information:**

Natalie Climo

Company Secretary, PainChek

[natalie.climo@boardroomlimited.com.au](mailto:natalie.climo@boardroomlimited.com.au)

02 8016 2875

Philip Daffas

CEO, PainChek

[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)

0406 537 235

**About Eldermark**

Eldermark is redefining senior living operations—uniting clinical intelligence, financial performance, and predictive analytics in one platform. Engineered for the business of care, Eldermark NEXT helps communities turn care into profit, generating up to \$1,263 in additional service revenue per resident each month. With over 30 years of experience, we give leaders real-time visibility, operating teams hours back, and residents better outcomes. Eldermark powers the future of senior living.

**About PainChek®**

[PainChek®](#) is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek’s detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,800 aged care facilities, with more than 10,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

For personal use only

- For personal use only
- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
  - Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
  - Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
  - Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>